![Michelle Morgan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Michelle Morgan
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Cebix, Inc.
![]() Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA.
3
| Extinct | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Michelle Morgan tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Chairman | |
INTERMUNE INC | Biotechnology | Director/Board Member | |
Elan Pharmaceuticals, LLC
![]() Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Director/Board Member | |
ArmaGen, Inc.
![]() ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Chief Executive Officer | |
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
Karolinska Institutet | College/University | Corporate Officer/Principal | |
ARYX THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
OCERA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
Creative Peptides Sweden AB
![]() Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Schwartz Pharma AG
![]() Schwartz Pharma AG Pharmaceuticals: MajorHealth Technology Schwartz Pharma AG is a German company. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Lausanne | College/University | Corporate Officer/Principal | |
University of Gothenburg | College/University | Doctorate Degree | |
Pharmacia GmbH | Private Equity Investor | ||
University of California | College/University | Doctorate Degree | |
Kalgene Pharmaceuticals, Inc.
![]() Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Medical/Nursing Services | Director/Board Member | |
PROTHENA CORPORATION PLC | Biotechnology | Director/Board Member | |
Prothena Biosciences, Inc.
![]() Prothena Biosciences, Inc. BiotechnologyHealth Technology Part of Prothena Corp. Plc, Prothena Biosciences, Inc. is a company that specializes in the biology of misfolded proteins. The company is based in South San Francisco, CA. The company has over 3 decades of expertise in this field and offer a range of services including science, pipeline, clinical trial information, and more. | Biotechnology | Chairman | |
XENETIC BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
SPARK THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
POSEIDA THERAPEUTICS, INC. | Biotechnology | Chairman | |
CODEMILL AB | Packaged Software | Comptroller/Controller/Auditor | |
AFYX Therapeutics AS
![]() AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Miscellaneous Commercial Services | Chairman | |
NURAVAX, INC.
![]() NURAVAX, INC. Miscellaneous Commercial ServicesCommercial Services The American company specializes in immunotherapy for neurodegenerative disorders. Nuravax aims to create a new segment in the market for the preventive treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) by developing safe and highly immunogenic preventive vaccines for preclinical PD/DLB and AD people based on a set of novel non-invasive and accurate disease biomarkers. The private company estimates the size of this market as approximately 40 million preclinical AD people at risk of disease. Nuravax is licensed for the patented multitep platform technology for the commercialization of prophylactic vaccines against all neurodegenerative disorders. The company is responsible for implementing co-development and sub-licensing agreements with larger biotech and pharmaceutical companies, and for further clinical validation of products. | Miscellaneous Commercial Services | Director/Board Member | |
Callaway Innovations | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Stati Uniti | 18 |
Svezia | 5 |
Irlanda | 4 |
Germania | 3 |
Svizzera | 2 |
Settori
Health Technology | 18 |
Consumer Services | 5 |
Health Services | 3 |
Commercial Services | 3 |
Finance | 2 |
Posizioni
Director/Board Member | 14 |
Independent Dir/Board Member | 10 |
Chairman | 6 |
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 5 |
Contatti più connessi
Insiders | |
---|---|
Lars Ekman | 21 |
James Callaway | 8 |
John Wahren | 4 |
- Borsa valori
- Insiders
- Michelle Morgan
- Connessioni Società